Cannabinoid pillar · precursor

Cannabigerolic acid (CBGa).

Before a cannabis plant makes THCA, CBDA or CBCA, it makes cannabigerolic acid: the acidic precursor the whole cannabinoid family is built from, and the reason CBG gets called the mother cannabinoid. How the plant uses CBGa is well-mapped biochemistry. What CBGa does on its own is a much younger story, and its pharmacology is still being catalogued.

Evidence library·21 studies·updated 9 August 2026·How we check
Reading depth
Origin & role

Everything begins with CBGa.

The route is short. Olivetolic acid meets geranyl pyrophosphate, and the plant has cannabigerolic acid (CBGa), its single precursor. Three synthase enzymes then pull it down separate branches into the THCA, CBDA and CBCA lines. Decarboxylation turns it into neutral CBG, which is simply CBGa without its carboxyl group.

Figure E · biosynthesis
The making of the mother cannabinoid
Demonstrated · plant biochemistry
Geranyl pyrophosphate and olivetolic acid combine, via a prenyltransferase, into CBGA — the mother acid. This upstream step is general biochemistry, drawn lighter because it is not yet in our registry. CBGA is then converted by THCA synthase into THCA (Sirikantaramas 2004), by CBDA synthase into CBDA (Taura 1996), and into CBCA — the synthases are not perfectly specific and also yield some CBCA (Zirpel 2018). Heat and time decarboxylate the acids into the neutral forms THC, CBD and CBC; Wang 2016 measured how fast THCA and CBDA do so.Precursorsplant building blocksMother acidthe acid form of CBGAcid formsmade in the plantNeutral formsafter heat + timeGPPgeranyl-PPolivetolicacidPrenyltransferasegeneral biochemistry · not yet in our registryCBGATHCA synthaseCBDA synthaseCBCA synthaseTHCACBDACBCASirikantaramas 2004Taura 1996Zirpel 2018THCA and CBDA synthasesalso make some CBCADecarboxylationheat + time · Wang 2016THCCBDCBCΔ⁹-THCcannabidiolcannabichromene
Geranyl pyrophosphate and olivetolic acid combine, via a prenyltransferase, into CBGA — the mother acid. This upstream step is general biochemistry, drawn lighter because it is not yet in our registry. CBGA is then converted by THCA synthase into THCA (Sirikantaramas 2004), by CBDA synthase into CBDA (Taura 1996), and into CBCA — the synthases are not perfectly specific and also yield some CBCA (Zirpel 2018). Heat and time decarboxylate the acids into the neutral forms THC, CBD and CBC; Wang 2016 measured how fast THCA and CBDA do so.Precursorsplant building blocksGPPgeranyl-PPolivetolicacidPrenyltransferasegeneral biochemistry ·not yet in our registryMother acidthe acid form of CBGCBGAAcid formsmade in the plantNeutral formsafter heat + timeDecarboxylationheat + time · Wang 2016THCAsynthaseTHCASirikantaramas 2004THCΔ⁹-THCCBDAsynthaseCBDATaura 1996CBDcannabidiolCBCAsynthaseCBCAZirpel 2018CBCcannabichromeneTHCA and CBDA synthasesalso make some CBCA
One mother acid, three branches: CBGA, the acid form of CBG, is where THCA, CBDA and CBCA begin. Each labelled step names the registry study behind it. The step that makes CBGA, from GPP and olivetolic acid, is drawn lighter: it is general biochemistry, and no primary study of that enzyme is in our registry yet. Sources: Taura 1996, Sirikantaramas 2004, Zirpel 2018, Wang 2016.

Ask the supplier: six questions about CBGa.

Six questions to put to a supplier, each followed by the position the registry or this compound's page already holds, in its own words. The questions ask what the supplier states; none asks what anyone should take. Informational only, not medical or legal advice.

1Is the figure on the certificate CBGA or CBG, and has the material been decarboxylated?
They are different rows: CBGA “Loses CO₂ (heat/time) → CBG”, so a product that has been heated is carrying a different molecule from the one on the drum.On the CBGa page →
2What human data does the supplier cite for CBGA itself?
The pillar's third tier is the answer: “Nobody has published a trial of isolated CBGa in people”. A gap in testing, not a finding against.On the CBGa page →
3How many milligrams of CBGA per serving, and against what?
The only trial exposure is co-presence inside a CBG product, where CBGA “was never the thing being tested”, so no human figure sizes a CBGA label.Not graded in our registryCuttler 2024 · On the CBGa page →
4Does the label claim a receptor or target effect for CBGA?
The registry's specimen row keeps them apart: “Biosynthesis characterized · pharmacology: catalogue in progress”.On the CBGa page →
5On what basis does the label say non-intoxicating?
The pillar's specimen row states it as identity, intoxicating: “No”, for the acid precursor as for CBG.On the CBGa page →
6What does the supplier say to a tested athlete about CBGA?
CBGA is measured in people after ordinary hemp-product intake, on a validated urine panel of “sixteen cannabinoids, CBGa among them”. Ask whether the supplier's athlete note covers the acid as well as CBG.Not graded in our registryMareck 2023 · On the CBGa page →

Take the answers to the paperwork: Read a COA, then test the label wording. How the site grades what it holds is on How we grade.

What's established

What is known about CBGa is biosynthesis.

That short route is also the best-documented part of CBGa's story. Researchers have cloned and characterized the branch enzymes and measured the decarboxylation kinetics, and a verified study stands behind every step.

In short, enzymes decide which family CBGa joins, and gentle heat decides whether it ends up as CBG. Switch to Researcher depth for the enzyme-level detail and citations.

Enzymatic branching → THCA · THCA synthasestudy type: Biochemistry

THCA synthase takes CBGA as its substrate and oxidatively cyclizes it into THCA. The enzyme has been molecularly cloned and expressed in a heterologous host.

Sirikantaramas et al. (2004) · Journal of Biological ChemistryPMID 15190053
Enzymatic branching → CBDA · CBDA synthasestudy type: Biochemistry

CBDA synthase, purified and characterized from Cannabis sativa, converts the same CBGA substrate into CBDA.

Taura et al. (1996) · Journal of Biological ChemistryPMID 8663284
Branch specificity · THCA / CBDA synthasestudy type: Biochemistry

Structure–function analysis of the branch synthases that act on CBGA, including evidence that the enzymes are imperfectly specific, which shapes which cannabinoids a plant ends up making.

Zirpel et al. (2018) · Journal of BiotechnologyPMID 30053500
Decarboxylation → CBG · heat / timestudy type: Biochemistry

Given heat and time, CBGA loses CO₂ and becomes neutral CBG, following temperature-dependent first-order kinetics, which is how a finished product can contain CBG that started out as CBGA.

Wang et al. (2016) · Cannabis and Cannabinoid ResearchPMID 28861498
Catalogue in progress, with early findings

CBGa's own receptor pharmacology trails far behind that of its products, so CBG Atlas assigns it no target profile yet. A few direct findings are published and verified, and they follow under direct pharmacology, cited without a grade. For a characterized receptor profile, look to its decarboxylated form, CBG.

Direct pharmacology

What CBGa itself has been measured doing.

Biosynthesis is the story of CBGa being turned into something. The newer question is what CBGa does when it acts on something itself. Two findings have been checked against their primary sources, and both still sit outside the registry's graded claims.

In short, the work so far is in cells and mice: one ion channel CBGa blocks, and one mouse seizure study whose result went both ways, helping in some tests and worsening seizures in others. None of it shows what CBGa does in a person, and none of it is a reason to take anything. Switch to Researcher depth for the findings and their citations.

2023

TRPM7 ion channel

In vitro · heterologous and native cells · Suzuki et al. · 2023 · Function (Oxf) 5(1):zqad069 · PMID 38162115

About half of a panel of major and minor cannabinoids suppressed TRPM7 currents to some degree, and CBGa was the strongest inhibitor in the set. Of the direct actions reported for CBGa in the sources we catalogue, this one is the most fully characterized. The inhibition needs a working TRPM7 kinase domain, is sensitized by intracellular Mg·ATP and by free magnesium, and weakens when intracellular calcium rises. CBGa also inhibited native TRPM7 currents in a B-lymphocyte cell line.

What this is not: Channel behaviour in cells, and nothing more. Reading it as an anti-inflammatory, anticancer or kidney finding, or as a treatment claim, outruns the data, and nobody has tested it in people.

Checked against its PubMed record and cited in prose. It has yet to enter the CBG Atlas registry as a graded entry, so it carries no evidence grade.

2021

Seizure threshold

Preclinical · mouse models of epilepsy · Anderson et al. · 2021 · British Journal of Pharmacology 178(24):4826–4841 · PMID 34384142

A screen of the cannabis plant for anticonvulsant phytocannabinoids found CBGa the most potent of those identified, and its effects diverged within the same study. CBGa was anticonvulsant against hyperthermia-induced and spontaneous seizures and in the maximal-electroshock threshold test, and it potentiated clobazam. It was proconvulsant in the 6-Hz threshold test, and a high dose increased spontaneous seizure frequency in the Scn1a mouse model. Tested against multiple epilepsy-relevant targets, CBGa showed reported interactions including GPR55, TRPV1 channels and GABA receptors.

What this is not: Mouse work, with a result that cuts both ways inside one paper. None of it is evidence that CBGa treats epilepsy or any seizure disorder. The proconvulsant finding is half the result, and dropping it to leave the anticonvulsant half standing alone would mislead.

Checked against its PubMed record and cited in prose. It has yet to enter the CBG Atlas registry as a graded entry, so it carries no evidence grade.

CBGa vs CBG

Same molecule, one CO₂ apart.

One carboxyl group separates them, and far more of the characterized pharmacology sits on the CBG side of it.

CBGa compared with CBG, property by property
PropertyCBGaCBG
Chemical formAcidic (carboxylic acid)Neutral (decarboxylated)
Molecular formulaC₂₂H₃₂O₄ · 360.49C₂₁H₃₂O₂ · 316.48
Biosynthetic roleThe precursor, branched into THCA/CBDA/CBCA and decarboxylated to CBGA product: the decarboxylated form of CBGa
ConversionLoses CO₂ (heat/time) → CBGFormed when CBGa decarboxylates
Characterized pharmacologyEarly: TRPM7 ion-channel inhibition in vitro (kinase-dependent); broader target profile catalogue in progressα2-adrenoceptor, 5-HT1A, CB1, TRP channels (in vitro)
Human evidenceExposure and co-presence: CBGa measured in human samples after hemp-product intake, and present in a product given to trial participants. No trial of isolated CBGa in people has been published, so efficacy is unshown.One small acute trial on anxiety and stress (Low); other human CBG research exists
IntoxicatingNoNo
The human record

Human data on CBGa exists. It is not efficacy data.

“No human evidence” is the usual summary, and it is wrong. CBGa has been measured in people, and it has been given to people inside a CBG product. What it lacks is a trial of its own. The distance between those three statements is the whole story, and none of them amounts to evidence of an effect.

Tier 1

Exposure: CBGa is measured in people

Mareck et al. · 2023 · Drug Testing and Analysis 15(1):27–41 · PMID 35633098

In a single-dose administration study approved by an ethics committee, participants consumed commercially available hemp products. Urine collected before and after was analysed with a validated panel of sixteen cannabinoids, CBGa among them, and showed variable patterns of cannabinoids and their metabolites.

What this does not establish: Analytical chemistry, showing that CBGa turns up in human samples after ordinary hemp-product intake; symptoms and conditions were outside its scope. The published abstract reports urinary results without breaking them out by cannabinoid, so a CBGa concentration will have to wait for someone with the primary source in hand.

Checked against its PubMed record and cited in prose. It has yet to enter the CBG Atlas registry as a graded entry, so it carries no evidence grade.

Tier 2

Co-presence: CBGa has been given to humans inside a CBG product

Cuttler et al. · 2024 · Scientific Reports · PMID 39003387

The human trial of CBG's effects on anxiety and stress used a tincture that, according to its own Methods section, also contained CBGa alongside CBG and β-caryophyllene. So participants did receive CBGa, as a minor constituent of a CBG product, but it was never the thing being tested.

From its Methods, verbatim: “The CBG tincture was composed of 10 mg/ml CBG, 0.89 mg/ml CBGA, 0.35 mg/ml β-caryophyllene.”

What this does not establish: The trial measured CBG. No arm of it varied CBGa, so none of its outcomes can be pinned on CBGa or used to grade it. What it contributes is one fact: CBGa has been present in a product given to people under trial conditions.

A graded entry in the CBG Atlas registry, graded for CBG rather than CBGa. Cited here for its published composition alone, it carries no CBGa evidence grade and supports no CBGa efficacy claim.

Tier 3

Isolated CBGa in humans: no published trial

Uncited: the absence is the finding

Nobody has published a trial of isolated CBGa in people: no efficacy trial, and no Phase-1 safety or dose-ranging study of CBGa on its own. Any question about what CBGa does for a person stops at this tier, and so far the tier has stayed empty.

What this does not establish: A gap in testing, which counts as evidence neither for nor against an effect. CBGa has not been trialled in people and found wanting. It has simply not been trialled.

How to read tier 3

Tier 3 is a gap in testing, and CBG Atlas leaves it open rather than fill it in either direction. The day an isolated-CBGa trial is published, the study will be checked and graded like any other, and this tier will change.

Graded studies

The evidence base.

Which leaves a short shelf of graded studies, all of them biosynthesis: how CBGa becomes the other cannabinoids. The pharmacology and human-record papers above are published and verified, and they sit outside the graded set.

Safety & practical

What is known about CBGa safety, and what is not?

What is uncertain

CBGa is non-intoxicating. No therapeutic effect of CBGa is established in humans, because nobody has yet run a trial of isolated CBGa; the question is open, which is different from settled against it. The human data that does exist measures exposure and co-presence rather than efficacy (see the human record). For a formulator, CBGa matters as the precursor. Heat converts it to CBG, so some of the CBG in a finished product can come from CBGa. Any cardiovascular caution (the α2-adrenoceptor blood-pressure note) applies to CBG, its decarboxylated form. This is educational information, not medical advice.

References

Sources for every claim.

Graded registry studies come first, each with its PubMed record. The papers cited in prose, ungraded, keep a list of their own.

2004

The gene controlling marijuana psychoactivity: molecular cloning and heterologous expression of Delta1-tetrahydrocannabinolic acid synthase from Cannabis sativa L.

Sirikantaramas et al. · Journal of Biological Chemistry · PMID 15190053
1996

Purification and characterization of cannabidiolic-acid synthase from Cannabis sativa L.

Taura et al. · Journal of Biological Chemistry · PMID 8663284
2018

Elucidation of structure-function relationship of THCA and CBDA synthase from Cannabis sativa L.

Zirpel et al. · Journal of Biotechnology · PMID 30053500
2016

Decarboxylation study of acidic cannabinoids: a novel approach using ultra-high-performance supercritical fluid chromatography/photodiode array-mass spectrometry

Wang et al. · Cannabis and Cannabinoid Research · PMID 28861498

Cited in the text, outside the graded evidence base

We checked every one against its PubMed record before citing it. None is a graded CBGa record in the registry export, so none carries an evidence grade.

2023

Risk of unintentional antidoping rule violations by consumption of hemp products

Mareck et al. · Drug Testing and Analysis 15(1):27–41 · PMID 35633098 · doi:10.1002/dta.3327

Analytical exposure data, showing that CBGa can be measured in human samples after controlled hemp-product intake. Effects on any condition lay outside what it measured, and it supports no efficacy claim.

Checked against its PubMed record and cited in prose. It has yet to enter the CBG Atlas registry as a graded entry, so it carries no evidence grade.

2024

Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial

Cuttler et al. · Scientific Reports · PMID 39003387 · doi:10.1038/s41598-024-66879-0

Cited for a single fact from its Methods: the tincture given to participants also contained CBGa. Its outcomes belong to CBG. CBGa was neither the intervention nor an isolated variable, so none of them can be attributed to it.

A graded entry in the CBG Atlas registry, graded for CBG rather than CBGa. Cited here for its published composition alone, it carries no CBGa evidence grade and supports no CBGa efficacy claim.

2023

Cannabigerolic Acid (CBGA) Inhibits the TRPM7 Ion Channel Through its Kinase Domain

Suzuki et al. · Function (Oxf) 5(1):zqad069 · PMID 38162115 · doi:10.1093/function/zqad069

A cell-level channel mechanism. The abstract's sentence on therapeutic potential is the authors' speculation, and we leave it with them; the paper supports no anti-inflammatory, anticancer or kidney claim.

Checked against its PubMed record and cited in prose. It has yet to enter the CBG Atlas registry as a graded entry, so it carries no evidence grade.

2021

Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy

Anderson et al. · British Journal of Pharmacology 178(24):4826–4841 · PMID 34384142 · doi:10.1111/bph.15661

Preclinical, in mice, and divergent within the one paper: anticonvulsant in some models, proconvulsant in another. Far too early for any human epilepsy or seizure claim, and the anticonvulsant half travels with the other or not at all.

Checked against its PubMed record and cited in prose. It has yet to enter the CBG Atlas registry as a graded entry, so it carries no evidence grade.

Identity & origin

Show the answers 4

What is CBGA?

CBGA (cannabigerolic acid) is the first cannabinoid the plant makes, a non-intoxicating acid it then converts into the precursors of THC, CBD and CBC, hence its billing as the "parent" cannabinoid. It lives in raw, unheated hemp. Heat decarboxylates it into CBG (cannabigerol), and its chemical identity is well established.

Established

What does CBGA (cannabigerolic acid) mean?

CBGA is short for cannabigerolic acid. The "-ic acid" ending, like the "A" in the abbreviation, flags the carboxylic-acid group that heat removes as CO₂. So CBGA is the acid form of CBG (cannabigerol): raw plants carry CBGA, and heating turns it into CBG.

Established

Where does CBGA come from — why is it the "mother of all cannabinoids"?

The plant builds CBGA from geranyl pyrophosphate and olivetolic acid, then hands it to dedicated synthase enzymes that turn it into THCA, CBDA and CBCA, the acids behind THC, CBD and CBC (Taura 1996; Sirikantaramas 2004; Zirpel 2018). All three branches grow from this one precursor, which is where the "mother" name comes from.

Catalogue in progress

Is CBGA natural (in raw cannabis)?

Yes. Living cannabis and hemp plants make CBGA, and in the raw plant the acid forms dominate: most cannabinoids exist as acids (CBGA, THCA, CBDA) until heat turns them into CBG, THC or CBD.

Established

Psychoactivity

Show the answers 4

Does CBGA get you high?

No. CBGA is the raw acid form, non-intoxicating and a different compound from THC. Heat turns it into CBG (cannabigerol), which is non-intoxicating as well, so neither form produces a THC-style high.

Established

Is CBGA psychoactive?

CBGA is non-intoxicating and isn't known to be psychoactive. As the raw acid precursor, it lacks THC's way of activating the CB₁ receptor to cause intoxication. Whether it has some subtle effect of its own on mood or cognition is an open question, with verified human data missing either way.

No primary evidence

What does CBGA do — what does it feel like?

CBGA has no established "feel." It is better understood as a biochemical building block, the precursor the plant turns into other cannabinoids, than as something people take for an effect. No controlled human study describes the experience, so any claim about how it feels is not established.

No primary evidence

Is raw CBGA active in the body?

So far, only in the lab. In cell studies, cannabinoid acids including CBGA inhibited an enzyme called DAGLα in vitro (De Petrocellis 2011), a preclinical finding rather than a demonstrated effect in people. Beyond early signals like that one, what CBGA does in the human body is largely uncharacterised, and our evidence catalogue is in progress.

Catalogue in progress

Legality

Show the answers 4

Effects & benefits

Show the answers 5

What are CBGA's benefits?

No health benefit of CBGA is established in humans. It is marketed as part of raw-cannabis "wellness" trends and has turned up in early laboratory work, but no controlled human study confirms any benefit. We report these as other people's claims, not as facts. General information, not medical advice.

No primary evidence

What is CBGA used for (raw-juicing trend)?

Mostly research, where it matters as a biochemical precursor. Consumers meet it through the raw-cannabis "juicing" trend, which promotes unheated leaves as a source of acidic cannabinoids. Proponents attach wellness claims to the practice, but those uses are not established by any controlled human evidence. Not medical advice.

No primary evidence

Can CBGA prevent or block COVID-19?

No, that is not established. A 2022 laboratory (in-vitro) study reported that CBGA and CBDA bound the SARS-CoV-2 spike protein in test-tube experiments. Binding in a test tube is not evidence that CBGA prevents, blocks or treats COVID-19 in people, and we have no primary evidence that CBGA does anything to SARS-CoV-2 in a human being. No such use is approved anywhere. General information, not medical advice.

No primary evidence

Is there human evidence for CBGA?

No verified human clinical evidence establishes any health effect of CBGA specifically. The solid science covers its chemistry and biosynthesis, how the plant makes it and what it becomes, and effect and benefit claims stay catalogue in progress until controlled human studies exist. Nobody has run the tests, which is a different thing from a test that failed. Not medical advice.

No primary evidence

Can CBGA help with inflammation?

Nobody has tested it, and we hold no CBGA inflammation study in people, animals or cells. Claims on this point usually borrow from research on CBG, the neutral cannabinoid CBGA becomes when heated, or from the wider cannabinoid literature. Neither transfers: CBGA is a separate molecule and has to earn evidence of its own.

No primary evidence

Safety & side effects

Show the answers 5

Is CBGA safe?

Nobody knows yet, because CBGA's safety is uncharacterised. No controlled human safety study has tested isolated CBGA, so long-term effects, safe amounts and risks are not established. Non-intoxicating is a statement about the high, and safety is a separate question, so "proven safe" is a claim CBGA has not earned. Consult a qualified professional before use. General information, not medical advice.

No primary evidence

What are the side effects of CBGA?

CBGA's side effects are not established. With no controlled human studies of isolated CBGA, whatever side effects it has remain formally undocumented. Raw-cannabis products that carry CBGA may cause general digestive or other effects. Report any adverse event and consult a professional. Not medical advice.

No primary evidence

Can you take too much CBGA?

Nobody knows, because no safe or maximum amount of CBGA has been established and no dose has been studied in humans. As with any supplement, more isn't necessarily better, and what high intake does is unknown. We give no dosing guidance; consult a qualified professional. General information, not medical advice.

No primary evidence

Does CBGA interact with medications?

It might, and the data to rule it out are missing: verified human studies hold no CBGA-specific drug-interaction data. Cannabinoids in general can affect drug-metabolising enzymes. If you take any medication, particularly cardiovascular or other prescription drugs, ask your doctor or pharmacist before using CBGA products. Not medical advice.

No primary evidence

Is there any human safety data for CBGA?

None for CBGA on its own: no Phase-1 study, no dose-ranging work, no interaction data. It has turned up in human urine after hemp-product intake, and in the tincture used in a CBG trial, so people are clearly exposed to it. Exposure and co-presence are all those findings show, and safety remains untested in people.

No primary evidence

Drug testing

Show the answers 3

Will CBGA show up on a drug test?

CBGA itself is outside what drug tests look for: standard tests screen for THC and its metabolite (THC-COOH). The catch is the product. Raw or full-spectrum hemp products that contain CBGA can also contain trace THC or THCA, and that could trigger a positive, so be cautious if you are tested.

Established

Does CBGA contain THC?

No. CBGA is a separate compound from THC and contains none. Hemp extracts and raw-cannabis products that contain CBGA may carry other cannabinoids as well, trace THC or THCA among them, depending on the source plant and the processing. A product's certificate of analysis shows what is actually in it.

Established

Can raw cannabinoids fail a drug test?

Possibly, though indirectly. Drug tests target THC rather than raw acid cannabinoids like CBGA, but raw or full-spectrum cannabis products can contain THCA and trace THC, and THCA turns into THC with heat or over time. Since THC is what tests detect, a positive result is possible.

Established

Usage & dosing

Show the answers 4

How do you take CBGA (raw juicing, tinctures)?

Mostly unheated, since heat converts CBGA into CBG. People juice fresh raw-cannabis leaves or use unheated tinctures and oils that keep the acid form intact. We describe the formats only, with no dosing advice and no product endorsement. General information, not medical advice.

Catalogue in progress

What CBGA products are there?

CBGA turns up mostly in raw or lightly processed hemp products: unheated full-spectrum tinctures and oils, raw-cannabis juice, and some isolate powders sold to formulators and researchers. Heat converts CBGA to CBG, so finished "activated" products hold little of it. The certificate of analysis shows how much acid a product actually contains.

Catalogue in progress

How much CBGA should I take?

No dose of CBGA has been established. No controlled human study has identified an effective or safe amount, so dosing stays catalogue in progress and we make no recommendation. The figure on a label reflects the manufacturer's choice and nothing more. Anyone considering CBGA products should talk to a qualified healthcare professional, especially if taking other medications. General information, not medical advice.

No primary evidence

Does CBGA need to be heated to work?

Only if the goal is CBG. Heating (decarboxylation, ~110–130 °C) is what turns CBGA into CBG; keeping CBGA means keeping the product unheated, because heat destroys the acid. Neither form has an established effect in humans, so "work" is a generous word either way.

Established

Comparisons

Show the answers 4

CBGA vs CBG — what's the difference (acid vs neutral)?

CBGA is the acidic, raw form; CBG (cannabigerol) is the neutral form left after decarboxylation. Heating CBGA to roughly 110–130 °C strips its carboxyl group off as CO₂ and turns it into CBG. Both are non-intoxicating, yet they are chemically distinct molecules, which makes raw and heated products different products.

Established

CBGA vs CBDA and THCA — how do they relate?

CBGA is the parent acid, and CBDA and THCA are made from it. Plant synthase enzymes convert CBGA into THCA, CBDA and CBCA (Taura 1996; Sirikantaramas 2004; Zirpel 2018), and heat then decarboxylates each one into THC, CBD and CBC respectively, leaving CBGA upstream of all of them.

Catalogue in progress

Raw vs decarbed cannabinoids — what's the difference?

Raw cannabinoids are the acids the living plant makes (CBGA, THCA, CBDA); decarbed, or decarboxylated, cannabinoids are their neutral forms after heating (CBG, THC, CBD), with a carboxyl group removed as CO₂. The chemical difference can change what they do: raw THCA is non-intoxicating, while decarbed THC intoxicates.

Established

Is CBGA or CBG better?

Neither has been shown to be better. CBGA is the raw precursor acid; CBG, its heated neutral form, has a verified in-vitro receptor profile, though neither has proven human health benefits. For now the choice is between a raw product and an activated one, and the evidence favours neither. General information, not medical advice.

No primary evidence

Chemistry & production

Show the answers 4

What is CBGA's formula and structure?

CBGA's molecular formula is C₂₂H₃₂O₄, with a molecular weight of about 360.49 g/mol and CAS number 25555-57-1. Structurally it is cannabigerol (CBG) plus a carboxylic-acid group, the part lost as CO₂ when decarboxylation forms CBG, and THCA and CBDA relate to THC and CBD in the same acid-to-neutral way.

Established

How is CBGA extracted?

From raw, unheated hemp, with cold or low-temperature methods, since heat would turn it into CBG. Common approaches are cold ethanol or CO₂ extraction, followed by careful processing that keeps the acid intact. Yields are usually low because the plant converts CBGA quickly into other cannabinoids.

Established

Is CBGA the precursor to THCA, CBDA, and CBCA?

Yes, and the biochemistry is well established. Plant synthase enzymes convert CBGA into THCA (THCA synthase; Sirikantaramas 2004) and CBDA (CBDA synthase; Taura 1996). Those synthases are imperfectly specific, which is how some CBCA appears as well (Zirpel 2018). The acids then decarboxylate into THC, CBD and CBC.

Catalogue in progress

At what temperature does CBGA turn into CBG (decarboxylation)?

At roughly 110–130 °C, where CBGA loses its carboxyl group as CO₂ and becomes CBG. Gentle heating at ~110 °C gets most of the conversion done in about 25–30 minutes. Higher temperatures work faster but risk degradation, and CBGA converts less efficiently than THCA (Wang 2016).

Demonstrated

Buying & trust

Show the answers 5

Where can I buy CBGA?

From a few specialty hemp brands, as raw, unheated ("full-spectrum, non-decarboxylated") tinctures and oils, and from chemical suppliers, as a reference isolate for researchers. Expect to look much harder than you would for CBD or CBG. We endorse no seller, and local legality is yours to check.

Catalogue in progress

Why is CBGA rare or expensive?

The plant converts CBGA into other cannabinoids quickly, so there is only ever a little of it, and only briefly. The acid is also unstable, turning into CBG when heated, so keeping it intact takes careful low-temperature handling. Low natural abundance plus specialised processing pushes the price up.

Established

How do I know a CBGA product is real (COA)?

Ask for a current certificate of analysis (COA) from an independent third-party lab. A useful one lists CBGA by name rather than folding it into CBG or "total cannabinoids," shows an amount that matches the label, and screens for contaminants such as pesticides, solvents and heavy metals. A missing or mismatched COA is a red flag.

Established

Is CBGA worth trying?

That's your call, made on thin evidence. CBGA is scientifically interesting as the "mother" precursor, and its biosynthesis is settled chemistry; its effects in people are not established, with no proven human health benefit behind any specific claim. If you are considering it, talk to a qualified professional and check local legality. General information, not medical advice.

No primary evidence

What should I look for when buying CBGA?

Start with a recent third-party COA that shows CBGA content and passes contaminant screening. Confirm the product really is raw or unheated, since heat converts CBGA to CBG, and look for clear labelling and sourcing. The product should also comply with your local law (e.g., ≤0.3% Δ⁹-THC where that applies). Be wary of health claims that sound too good.

Established

Before you act on what you read about CBGa

Informational only, not medical advice. CBG Atlas is a scientific reference. Nothing here diagnoses, treats, cures or prevents any disease. Every claim on the page carries the grade of the evidence behind it, and the grade sets the words the claim may use. How we grade evidence.

Cardiovascular note. CBG is a potent α2-adrenoceptor agonist in vitro, and α2 agonism can lower blood pressure. Anyone taking blood-pressure or other cardiovascular medication should consult a clinician before use. This is educational information, not medical advice.

Funding and independence. Peregrine Biopharma funds the platform and holds no editorial authority.

Report a safety event →
Compound monographs

The rest of the family.

Seven compounds, each with its own monograph. The line under each one is what the verified registry actually holds for it — including where that is nothing yet.

Cannabigerol (CBG)

The mother cannabinoid. CBGa decarboxylates to CBG, and both occur in the plant. The three synthases act on CBGa, the acid, branching it into THC, CBD and CBC. CBG carries more evidence than any other compound on the platform.

21 verified studies in the registry

Cannabigerovarin (CBGV)

The propyl (varin) analogue of CBG, with a three-carbon side chain in place of five.

Catalogue in progress: no study specific to this compound in the registry yet

Cannabichromene (CBC)

One of the three branches off the shared CBGA substrate, and a non-intoxicating one.

Catalogue in progress: no study specific to this compound in the registry yet

Cannabinol (CBN)

Forms as THC ages and oxidises, so it builds up in stored material rather than being made by the plant directly.

Catalogue in progress: no study specific to this compound in the registry yet

Cannabidivarin (CBDV)

CBD's propyl analogue, and the varin with the largest published human trial record.

Catalogue in progress: no study specific to this compound in the registry yet

Tetrahydrocannabivarin (THCV)

THC's propyl analogue, which in laboratory work behaves differently from THC at its receptors.

1 verified study in the registry